Literature DB >> 34105255

The role of RNA editing enzyme ADAR1 in human disease.

Brian Song1, Yusuke Shiromoto1, Moeko Minakuchi1, Kazuko Nishikura1.   

Abstract

Adenosine deaminase acting on RNA (ADAR) catalyzes the posttranscriptional conversion of adenosine to inosine in double-stranded RNA (dsRNA), which can lead to the creation of missense mutations in coding sequences. Recent studies show that editing-dependent functions of ADAR1 protect dsRNA from dsRNA-sensing molecules and inhibit innate immunity and the interferon-mediated response. Deficiency in these ADAR1 functions underlie the pathogenesis of autoinflammatory diseases such as the type I interferonopathies Aicardi-Goutieres syndrome and dyschromatosis symmetrica hereditaria. ADAR1-mediated editing of endogenous coding and noncoding RNA as well as ADAR1 editing-independent interactions with DICER can also have oncogenic or tumor suppressive effects that affect tumor proliferation, invasion, and response to immunotherapy. The combination of proviral and antiviral roles played by ADAR1 in repressing the interferon response and editing viral RNAs alters viral morphogenesis and cell susceptibility to infection. This review analyzes the structure and function of ADAR1 with a focus on its position in human disease pathways and the mechanisms of its disease-associated effects. This article is categorized under: RNA in Disease and Development > RNA in Disease RNA Processing > RNA Editing and Modification RNA Interactions with Proteins and Other Molecules > Protein-RNA Interactions: Functional Implications.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  ADAR1; AGS; RNA editing; human disease; innate immunity

Mesh:

Substances:

Year:  2021        PMID: 34105255      PMCID: PMC8651834          DOI: 10.1002/wrna.1665

Source DB:  PubMed          Journal:  Wiley Interdiscip Rev RNA        ISSN: 1757-7004            Impact factor:   9.957


  137 in total

1.  A developmentally regulated activity that unwinds RNA duplexes.

Authors:  B L Bass; H Weintraub
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

2.  ADAR1: A New Target for Immuno-oncology Therapy.

Authors:  Amruta Bhate; Tao Sun; Jin Billy Li
Journal:  Mol Cell       Date:  2019-03-07       Impact factor: 17.970

3.  A double-stranded RNA unwinding activity introduces structural alterations by means of adenosine to inosine conversions in mammalian cells and Xenopus eggs.

Authors:  R W Wagner; J E Smith; B S Cooperman; K Nishikura
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

Review 4.  Functions and regulation of RNA editing by ADAR deaminases.

Authors:  Kazuko Nishikura
Journal:  Annu Rev Biochem       Date:  2010       Impact factor: 23.643

5.  ADAR1-mediated RNA editing is required for thymic self-tolerance and inhibition of autoimmunity.

Authors:  Taisuke Nakahama; Yuki Kato; Jung In Kim; Tuangtong Vongpipatana; Yutaka Suzuki; Carl R Walkley; Yukio Kawahara
Journal:  EMBO Rep       Date:  2018-10-25       Impact factor: 8.807

Review 6.  The Editor's I on Disease Development.

Authors:  Mamta Jain; Michael F Jantsch; Konstantin Licht
Journal:  Trends Genet       Date:  2019-10-22       Impact factor: 11.639

Review 7.  Comparative virology of HTLV-1 and HTLV-2.

Authors:  Michael P Martinez; Jacob Al-Saleem; Patrick L Green
Journal:  Retrovirology       Date:  2019-08-07       Impact factor: 4.602

8.  A high resolution A-to-I editing map in the mouse identifies editing events controlled by pre-mRNA splicing.

Authors:  Konstantin Licht; Utkarsh Kapoor; Fabian Amman; Ernesto Picardi; David Martin; Prajakta Bajad; Michael F Jantsch
Journal:  Genome Res       Date:  2019-08-19       Impact factor: 9.043

9.  Asymmetric dimerization of adenosine deaminase acting on RNA facilitates substrate recognition.

Authors:  Alexander S Thuy-Boun; Justin M Thomas; Herra L Grajo; Cody M Palumbo; SeHee Park; Luan T Nguyen; Andrew J Fisher; Peter A Beal
Journal:  Nucleic Acids Res       Date:  2020-08-20       Impact factor: 16.971

10.  ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity.

Authors:  Julia Ramírez-Moya; Allison R Baker; Frank J Slack; Pilar Santisteban
Journal:  Oncogene       Date:  2020-03-10       Impact factor: 9.867

View more
  7 in total

1.  Case Report: Aicardi-Goutières Syndrome Type 6 and Dyschromatosis Symmetrica Hereditaria With Congenital Heart Disease and Mitral Valve Calcification - Phenotypic Variants Caused by Adenosine Deaminase Acting on the RNA 1 Gene Homozygous Mutations.

Authors:  Lingjuan Liu; Lu Zhang; Peng Huang; Jie Xiong; Yangyang Xiao; Cheng Wang; Dingan Mao; Liqun Liu
Journal:  Front Pediatr       Date:  2022-06-27       Impact factor: 3.569

Review 2.  Pathophysiological Role of Nucleic Acid-Sensing Pattern Recognition Receptors in Inflammatory Diseases.

Authors:  Norisuke Kano; Guang Han Ong; Daisuke Ori; Taro Kawai
Journal:  Front Cell Infect Microbiol       Date:  2022-06-06       Impact factor: 6.073

Review 3.  The importance of RNA modifications: From cells to muscle physiology.

Authors:  Anindhya Sundar Das; Juan D Alfonzo; Federica Accornero
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-10-19       Impact factor: 9.349

Review 4.  Autoimmunity and Cancer-Two Sides of the Same Coin.

Authors:  Justyna Sakowska; Łukasz Arcimowicz; Martyna Jankowiak; Ines Papak; Aleksandra Markiewicz; Katarzyna Dziubek; Małgorzata Kurkowiak; Sachin Kote; Karolina Kaźmierczak-Siedlecka; Karol Połom; Natalia Marek-Trzonkowska; Piotr Trzonkowski
Journal:  Front Immunol       Date:  2022-05-13       Impact factor: 8.786

5.  ADAR1 averts fatal type I interferon induction by ZBP1.

Authors:  Huipeng Jiao; Laurens Wachsmuth; Simone Wolf; Juliane Lohmann; Masahiro Nagata; Göksu Gökberk Kaya; Nikos Oikonomou; Vangelis Kondylis; Manuel Rogg; Martin Diebold; Simon E Tröder; Branko Zevnik; Marco Prinz; Christoph Schell; George R Young; George Kassiotis; Manolis Pasparakis
Journal:  Nature       Date:  2022-07-20       Impact factor: 69.504

Review 6.  ADAR2 enzymes: efficient site-specific RNA editors with gene therapy aspirations.

Authors:  Khadija Hajji; Jiří Sedmík; Anna Cherian; Damiano Amoruso; Liam P Keegan; Mary A O'Connell
Journal:  RNA       Date:  2022-07-21       Impact factor: 5.636

Review 7.  ADAR1-Mediated RNA Editing and Its Role in Cancer.

Authors:  Jizhe Liu; Fei Wang; Yindan Zhang; Jingfeng Liu; Bixing Zhao
Journal:  Front Cell Dev Biol       Date:  2022-07-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.